Ecrins Therapeutics’ first fundraising entirely crowdfunded by WiSEED

11/05/2015 - 4 minutes

Ecrins Therapeutics, the company we interviewed last week, has successfully finished its first crowdfunding fundraiser, reaching €535k on WiSEED’s platform. The capital will allow the company to launch the large-scale chemical synthesis and regulatory toxicology studies, essential groundwork for the start of clinical Phase I/IIa. A second fundraise is already programmed in 2016 to finance these clinical studies.

WiSEED is a pioneer platform of equity crowdfunding that allows individuals to invest in technology start-ups, particularly in the biotech and medtech fields. So far, the platform has financed eight companies already. We exclusively interviewed Dr. Louise Chopinet, Health and Development Manager at WiSEED, about Écrins fundraising and the platform.

Dr. Chopinet, who has a Ph.D. in biophysics applied to gene vectorization, stated: “We are pleased to have participated in the capital increase of this young company and to contribute to the development of its flagship product, ET-D5. Subscriptions are from many individuals, who, beyond the financial interest, the investment was in line with their personal commitment to contribute to the fight against cancer”.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member